# Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

> **NCT04358068** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 20 (actual)

## Conditions studied

- COVID-19
- SARS-CoV 2

## Interventions

- **DRUG:** Hydroxychloroquine (HCQ)
- **DRUG:** Azithromycin (Azithro)
- **DRUG:** Placebo for Hydroxychloroquine
- **DRUG:** Placebo for Azithromycin

## Key facts

- **NCT ID:** NCT04358068
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-05-13
- **Primary completion:** 2020-07-08
- **Final completion:** 2020-07-08
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Slow enrollment and lack of community enthusiasm
- **Last updated:** 2021-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358068, "Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04358068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*